comprehensive -WSS

comprehensive

author：explore 2025-09-27 23:02:46 - browse：94

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Doulas covered by Medicaid under New York's new plan

WSS

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

The SUPPORT Act is critical to fighting the opioid crisis

Update the Apgar Score to remove skin color

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

focus

comprehensive

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

How I ended up pumping milk in a bathroom stall at JPM 2024

Medicare proposal to cover medical devices draws a mixed reaction

Immunocompromised patients offer clues on chronic Covid

Walensky prepares to leave CDC — and Congress — behind

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

What does generative AI mean for health care? We asked experts

New Medicare drug pricing powers could soon be upended in court

Walensky prepares to leave CDC — and Congress — behind

JPM 2024: Nvidia claims we're in biological revolution. Are we?

entertainment

HPV vaccine, cervical cancer study delivers historic results

High breast density mammograms need follow

The nurse manager staffing crisis is hurting patients

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Risky weight loss products often used by teens globally, per study

A pediatrician calls for Congress to pass the child tax credit deal

focus

explore

hotspot

knowledge